GenScript ProBio announced that it has received $220,000,000 in its Series C round of funding led by Legend Capital Management Co., Ltd. on January 18, 2023. The transaction included participation from HighLight Capital, GF Xinde Investment Management Co., Ltd, GL Ventures, Xiamen C&D Inc., Shanghai New Alliance Investment Management Co., Ltd., Huatai Zijin Investment Co. Ltd and China Industrial International Trust Asset Management Limited.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
10.33 CNY | -6.94% | -0.96% | +7.27% |
30/04 | Xiamen C&D's Q1 Profit Falls 24% | MT |
29/04 | Xiamen C&D Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.27% | 4.29B | |
+48.48% | 89.16B | |
+55.57% | 80.16B | |
+26.63% | 67.75B | |
+9.22% | 42.65B | |
+37.31% | 33.07B | |
+32.87% | 32.66B | |
+14.59% | 17.57B | |
-4.70% | 12.97B | |
+31.65% | 5.99B |
- Stock Market
- Equities
- 600153 Stock
- News Xiamen C&D Inc.
- GenScript ProBio announced that it has received $220 million in funding from a group of investors